An end to lawsuit is positive for Novo Nordisk, says analyst
Novo Nordisk gets out of a billion-dollar lawsuit in Denmark without paying plaintiffs or admitting wrongdoing. This is positive, says Analyst Søren Løntoft Hansen.
by marketwire, translated by daniel pedersen
On Friday, pharmaceutical firm Novo Nordisk settled a securities lawsuit in which shareholders had alleged Novo Nordisk had misled them about the insulin sales pressure on the US market and what this would mean for future sales.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk settles securities lawsuit in Denmark
For subscribers
